3/6
06:24 pm
itos
Rating for ITOS
Low
Report
Rating for ITOS
3/6
06:24 pm
itos
Rating for ITOS
Low
Report
Rating for ITOS
3/6
11:14 am
itos
Rating for ITOS
Low
Report
Rating for ITOS
3/6
08:12 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
3/5
06:09 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
3/5
06:09 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
1/16
07:44 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
1/10
08:13 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
1/10
08:13 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.